Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateScribe Therapeutics Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Flagged at $17.14 at 07:32 AM on Oct 08, then ran to $19.75 +15% that session.
The high is the session peak after our first alert, not a realized trade. Not investment advice.
Why is SCTX down today? It is at $15.40 (-14.23%), and our scanner flagged it 138 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment SCTX spikes, and full due diligence on SCTX — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $SCTX 138 times in the last 30 days. Create a free account to track $SCTX, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on SCTX from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
Likely catalystScribe Therapeutics, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from the latest SEC filing. Read it →A share sale has already completed, so that supply is out there. Size not stated in the filing.
Some filings did not state a size, so these are floors.
Recent priced share offering — a one-time sale that has already completed (not ongoing)
Priced at $15/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Aghazadeh Behzad Director | Bought (open market) | +8K 0.04% of company | added 0.3% | 3.09M | $144K at $18.25 | Jul 28, 26 |
Doudna Jennifer A Beneficial Owner (10%) | Acquired (grant/award) | +13K 0.07% of company | added 2.1% | 604K | n/a | Jul 27, 26 |
Orbimed Advisors Llc Director | Acquired (grant/award) | +349K 1.8% of company | n/a | 349K | n/a | Jul 27, 26 |
Orbimed Advisors Llc Director | Bought (open market) | +1.00M 5.3% of company | added 100% | 1.35M | $15.0M at $15.00 | Jul 27, 26 |
Gordon Carl L Director | Acquired (grant/award) | +349K 1.8% of company | n/a | 349K | n/a | Jul 27, 26 |
Gordon Carl L Director | Bought (open market) | +1.00M 5.3% of company | added 100% | 1.35M | $15.0M at $15.00 | Jul 27, 26 |
Ah Bio Fund Ii, L.P. Beneficial Owner (10%) | Acquired (grant/award) | +2.75M 14.5% of company | n/a | 2.05M | n/a | Jul 27, 26 |
Ah Bio Fund Ii, L.P. Beneficial Owner (10%) | Bought (open market) | +333K 1.8% of company | added 12% | 3.08M | $5.0M at $15.00 | Jul 27, 26 |
Aghazadeh Behzad Director | Bought (open market) | +2.38M 12.6% of company | added 100% | 3.08M | $35.7M at $15.00 | Jul 24, 26 |
Parrot David Officer | Bought (open market) | +3K 0.01% of company | n/a | 3K | $40K at $15.00 | Jul 23, 26 |
Lucas Svetlana Officer | Bought (open market) | +3K 0.02% of company | n/a | 3K | $45K at $15.00 | Jul 23, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on SCTX from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
SCTX last traded at $15.40, down 14.23% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Scribe Therapeutics Inc. Common Stock (SCTX) is next expected to report earnings on Wednesday, December 2, 2026, about 38 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The SCTX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged SCTX 138 times in the last 30 days.
SCTX (Scribe Therapeutics Inc. Common Stock) trades on XNAS, with a market cap of about $292M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge SCTX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$SCTX discussion
Sign in to ask a question or join the discussion.